Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Hal Chapman
Idiopathic Pulmonary Fibrosis
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging
Phase I study is to assess the safety of a purified from green tea, EGCG, in patients
with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary
fibrosis. expand
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis. Type: Interventional Start Date: Aug 2023 |
|
Prostate Cancer Genetic Risk Evaluation and Screening Study
Massachusetts General Hospital
Prostatic Neoplasm
Prostate Cancer
BRCA2 Mutation
BRCA1 Mutation
ATM Gene Mutation
This study aims to define the natural history of men at high genetic risk for prostate
cancer on the basis of specific germline genetic mutations, family history, or
Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The
hypothesis is that this targeted population1 expand
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations. Type: Observational [Patient Registry] Start Date: Feb 2020 |
|
PACE CF, a 3-session Mind-body Pain Management Program for Adults with Cystic Fibrosis
Massachusetts General Hospital
Cystic Fibrosis (CF)
Pain Management
Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes
unrecognized and under-managed in people with CF. Both medication and non-medication
interventions can be used to treat pain and ideally, there is a multicomponent management
approach.
The goal of this study i1 expand
Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes unrecognized and under-managed in people with CF. Both medication and non-medication interventions can be used to treat pain and ideally, there is a multicomponent management approach. The goal of this study is to pilot a new 3-session non-medication mind-body pain management intervention specifically designed for adults with cystic fibrosis (CF). The intervention is titled Pain Acknowledgement Coping and Empowerment in CF (PACE CF). PACE CF will be administered by a member of the CF care team via telehealth visits to participants at home or during a hospitalization. The aim of the study is to evaluate the feasibility and patient acceptability of the intervention as well as preliminary evidence of the impact of the intervention on pain and its interference in daily life. The study will also examine outcomes such as perceived coping, quality of life, symptoms of depression or anxiety, and use of prescribed pain medication, in an exploratory manner. Type: Interventional Start Date: Sep 2024 |
|
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzh1
Massachusetts General Hospital
Alzheimer Disease
Family Members
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein
deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
Gamma waves are important for memory, and in patients with AD, there are fewer gamma
waves in the brain. The Tsai lab found th1 expand
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease. Type: Interventional Start Date: Jan 2024 |
|
Cortical-Basal Ganglia Speech Networks
Massachusetts General Hospital
Parkinson Disease
Essential Tremor
Dystonia
In this research study the researchers want to learn more about brain activity related to
speech perception and production. expand
In this research study the researchers want to learn more about brain activity related to speech perception and production. Type: Interventional Start Date: Oct 2020 |
|
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
Massachusetts General Hospital
Anxiety Disorders
Psychotic Disorders
Depressive Disorder
Psychosocial Functioning
This research study aims to develop a brief group-based treatment called Resilience
Training for Teens, then to test how well it protects high school students with mild
symptoms of depression, anxiety, or having unusual feelings from developing mental
illnesses. expand
This research study aims to develop a brief group-based treatment called Resilience Training for Teens, then to test how well it protects high school students with mild symptoms of depression, anxiety, or having unusual feelings from developing mental illnesses. Type: Interventional Start Date: Mar 2024 |
|
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Th1
LimFlow, Inc.
Critical Limb Ischemia
Chronic Limb-Threatening Ischemia
Peripheral Arterial Disease
A prospective, single-arm, multi-center study designed to gather additional information
on the LimFlow System. expand
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System. Type: Interventional Start Date: Dec 2022 |
|
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
Massachusetts General Hospital
Heart Failure With Normal Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Heart Failure, Right Sided
Heart Failure With Mid Range Ejection Fraction
Cardiovascular Risk Factor
In this single-center, longitudinal observational study, we will comprehensively examine
clinical characteristics, proteomic, metabolomic, genomic and imaging data to better
understand how different heart failure types may develop and progress over time. We will
evaluate distinct sub-groups of hear1 expand
In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure. Type: Observational [Patient Registry] Start Date: Apr 2016 |
|
Phenotyping Asthma for Bronchial Thermoplasty
Massachusetts General Hospital
Severe Asthma
This study will evaluate a new imaging technology, called optical coherence tomography
(OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is
a new treatment option for severe asthmatic patients. The aim of this study is to learn
more about how airways respond to t1 expand
This study will evaluate a new imaging technology, called optical coherence tomography (OCT) to examine the asthmatic airways before and after bronchial thermoplasty, which is a new treatment option for severe asthmatic patients. The aim of this study is to learn more about how airways respond to this new treatment. In the future the investigators hope OCT will aid clinicians in the initial assessment, management and long-term follow up of patients receiving bronchial thermoplasty. Type: Observational Start Date: May 2021 |
|
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, a1
Michael Shy
Charcot Marie Tooth Disease
This is an observational longitudinal study to determine the natural history and
genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth
disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).
The investigators will also be determine the capability of the1 expand
This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C). The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window Type: Observational Start Date: Apr 2010 |
|
Mismatch vs. Standard Intervention During Memory Reconsolidation Blockade With Propranolol: Effect1
Massachusetts General Hospital
Stress Disorders, Post-Traumatic
The proposed R21 project will attempt to further develop a novel intervention for
posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in
normal humans has shown that when a stable, consolidated memory is reactivated (i.e.,
retrieved) under appropriate conditions, i1 expand
The proposed R21 project will attempt to further develop a novel intervention for posttraumatic stress symptoms inspired by the science of memory reconsolidation. Work in normal humans has shown that when a stable, consolidated memory is reactivated (i.e., retrieved) under appropriate conditions, it reverts to an unstable state, a process referred to herein as deconsolidation. In such a state, the memory is susceptible to the action of various "amnestic" agents that may inhibit its reconsolidation, thereby weakening it. The β-adrenergic blocker propranolol (PPNL) possesses such amnestic properties. More recent research has found that in order to initiate deconsolidation, there must be a prediction error, or mismatch, between what is expected and what occurs when the memory is reactivated. Prior placebo-controlled, randomized clinical trials (PBO-RCT) from our laboratory have found that when propranolol is administered concomitant with the reactivation of a psychologically traumatic memory, the memory is weakened, as revealed by subsequent lower physiological (heart rate, skin conductance, facial electromyogram) responding during script-driven mental imagery. Clinical applicability was evaluated in a PBO-RCT, in which PTSD participants receiving propranolol underwent six weekly sessions of 10-20 min of "standard" (STD) traumatic memory reactivation stimulated by reading a narrative. At post-treatment, these participants showed a greater reduction of PTSD symptoms compared to participants who had taken PBO. The goal of the proposed study is to test whether intentionally incorporating innovative mismatch (MM) into traumatic memory reactivation can improve upon physiological responding during script-driven mental imagery. Participants will be randomized to one of 2 treatment arms: STD/PPNL and MM/PPNL. A baseline assessment will measure psychophysiological responsivity to script-driven mental imagery (target measure). PPNL will be administered 90-min prior to each of six weekly 10-20 min. traumatic memory reactivation sessions. In the MM condition, a different, unexpected mismatch (e.g., singing the narrative) will be incorporated into the reactivation. In the STD condition, the participant will read the narrative the same way each time. The focus of the R21 proposal will be to assess whether the MM/PPNL group shows lower subsequent physiological responses than the STD/PPNL group Type: Interventional Start Date: Jun 2023 |
|
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
Metastatic Urothelial Carcinoma
Bladder Cancer
This research study is examining the effectiveness of pembrolizumab plus cryoablation or
aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer,
that has spread. expand
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread. Type: Interventional Start Date: Jun 2021 |
|
Strengthening of the First Dorsal Interosseous for Thumb Carpometacarpal Osteoarthritis
Massachusetts General Hospital
Thumb Osteoarthritis
First Dorsal Interosseous Strengthening
To determine the effect of first dorsal interosseus (FDI) strengthening in patients with
thumb carpometacarpal (CMC) osteoarthritis. expand
To determine the effect of first dorsal interosseus (FDI) strengthening in patients with thumb carpometacarpal (CMC) osteoarthritis. Type: Interventional Start Date: Dec 2016 |
|
Neuromodulation of Executive Function in the ADHD Brain
Massachusetts General Hospital
Attention Deficit Hyperactivity Disorder
This study aims to determine the transient, modulatory effects of transcranial direct
current stimulation (tDCS) on executive function and inhibitory control in patients with
ADHD compared to healthy controls. expand
This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD compared to healthy controls. Type: Interventional Start Date: Sep 2014 |
|
Metastatic Tumor Research and Outcomes Network
AO Innovation Translation Center
Metastatic Spine Tumor
The registry aims to collect patient information such as patient demographics,
co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on
adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). expand
The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s). Type: Observational [Patient Registry] Start Date: Nov 2017 |
|
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Erasmus Medical Center
Glioblastoma, IDH-wildtype
Glioblastoma
Glioblastoma Multiforme of Brain
Astrocytoma, Malignant
Brain Neoplasms
Resection of glioblastoma in or near functional brain tissue is challenging because of
the proximity of important structures to the tumor site. To pursue maximal resection in a
safe manner, mapping methods have been developed to test for motor and language function
during the operation. Previous ev1 expand
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM). Type: Observational Start Date: Jan 2023 |
|
The Acute Burn ResUscitation Multicenter Prospective Trial
American Burn Association
Burn Injury
This is a prospective randomized multi-center study which will compare acute fluid
resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR
alone), in adults with an acute burn involving at least 25% of their total body surface
area. expand
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area. Type: Interventional Start Date: Apr 2021 |
|
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndro1
Cullinan Therapeutics Inc.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in
patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic
Syndrome (MDS) expand
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Type: Interventional Start Date: Nov 2021 |
|
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Jasper Gerritsen
Glioblastoma
Glioblastoma Multiforme
Glioblastoma, IDH-wildtype
Glioblastoma Multiforme, Adult
There is no consensus on the optimal treatment of patients with high-grade glioma,
especially when patients have limited functioning performance at presentation (KPS ≤70).
Therefore, there are varied practice patterns around pursuing biopsy, resection, or
palliation (best supportive care). This stu1 expand
There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. Type: Observational Start Date: Jan 2023 |
|
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Jasper Gerritsen
Glioblastoma
Glioblastoma, IDH-wildtype
Glioblastoma Multiforme
Glioblastoma Multiforme, Adult
Glioblastoma Multiforme of Brain
There are no guidelines or prospective studies defining the optimal surgical treatment
for gliomas of older patients (≥70 years) or those with limited functioning performance
at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is
varied, amongst neurosurgeons internation1 expand
There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. Type: Observational Start Date: Jan 2023 |
|
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Grow1
Massachusetts General Hospital
Hemangioma
The purpose of this study is to find out if pulsed dye laser treatment or timolol maleate
0.5% gel can help infants who have a hemangioma. The investigators also want to find out
if pulsed dye laser treatment and timolol maleate 0.5% gel are safe to use without
causing too many side effects.
Heman1 expand
The purpose of this study is to find out if pulsed dye laser treatment or timolol maleate 0.5% gel can help infants who have a hemangioma. The investigators also want to find out if pulsed dye laser treatment and timolol maleate 0.5% gel are safe to use without causing too many side effects. Hemangioma is a common type of birthmark. These birthmarks happen when many new blood vessels grow in a specific area on the skin. Blood vessels are tiny tubes that carry blood through the body. No one knows what causes blood vessels to group together. Most birthmarks don't hurt at all and they usually aren't a sign of any kind of illness. Lots of newborns have these birthmarks on their bodies, like between the eyebrows. These birthmarks usually disappear within the first few months to years of life. These birthmarks tend to disappear spontaneously. Most hemangiomas are not treated unless the hemangioma threatens the child's health, which occurs in about 1 in 3 children with hemagiomas. Pulsed dye laser is widely used in children, and is approved by the U.S. Food and Drug Administration (FDA) for treating hemangioma. The FDA has approved timolol maleate to treat glaucoma in adults, but the FDA has not approved timolol maleate to treat hemangiomas in children. About 7 infants with hemangiomas have received timolol maleate. The results so far show that timolol maleate may be helpful and safe in treating hemangiomas in infants. An important question being tested in this study is whether pulsed-dye laser or timolol maleate can prevent hemangioma from growing when used very early after birth. Type: Interventional Start Date: Feb 2011 |
|
Biomarker Development for Muscular Dystrophies
Massachusetts General Hospital
Myotonic Dystrophy
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Current methods of measuring the response to new treatments for muscular dystrophies
involve the examination of small pieces of muscle tissue called biopsies. The
investigators are interested in finding less invasive methods that reduce the need for
muscle biopsies. The purpose of this research is1 expand
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases. Type: Observational Start Date: Feb 2015 |
|
Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness
Massachusetts General Hospital
Psychosis
Schizophrenia
The proposed research will test the hypothesis that objective social isolation and
loneliness are linked to neurobehavioral mechanisms involved in social perception and
motivation in individuals with and without serious mental illness. Moreover, it will
investigate the specific dynamic interactions1 expand
The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions among these experiences in daily life and how they, and their neurobehavioral predictors, are linked to day-to-day functioning. The findings of this project could provide novel targets for therapeutics aimed at improving functioning and overall quality of life in individuals with serious mental illnesses, as well as quantitative phenotypes for use in early detection efforts. Type: Interventional Start Date: Jul 2022 |
|
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliar1
Massachusetts General Hospital
Hepatocellular Carcinoma
Biliary Tract Cancer
This research study is studying a combination of drugs as a possible treatment for
Hepatocellular Carcinoma or Biliary Tract Cancer.
The interventions involved in this study are:
- Durvalumab
- Tremelimumab
- Radiation Therapy expand
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: - Durvalumab - Tremelimumab - Radiation Therapy Type: Interventional Start Date: May 2018 |
|
Effect of Theophylline in Pseudohypoparathyroidism
Massachusetts General Hospital
PHP Ia
PHP IB
Php1C
The study evaluates the effect of theophylline in 100 subjects with
Pseudohypoparathyroidism. expand
The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism. Type: Interventional Start Date: Nov 2019 |